China Universal Asset Management Co. Ltd. Has $285,000 Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

China Universal Asset Management Co. Ltd. raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 11.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 33,336 shares of the biopharmaceutical company’s stock after purchasing an additional 3,347 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Ocular Therapeutix were worth $285,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OCUL. SG Americas Securities LLC raised its stake in Ocular Therapeutix by 58.7% during the fourth quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company’s stock worth $612,000 after buying an additional 26,511 shares during the last quarter. RoundAngle Advisors LLC bought a new position in shares of Ocular Therapeutix in the 4th quarter worth about $1,695,000. Courier Capital LLC acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at about $482,000. Barclays PLC boosted its position in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company’s stock valued at $4,451,000 after purchasing an additional 138,441 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Ocular Therapeutix by 47.1% during the third quarter. Wellington Management Group LLP now owns 462,864 shares of the biopharmaceutical company’s stock worth $4,027,000 after purchasing an additional 148,310 shares during the period. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the sale, the insider now directly owns 269,059 shares of the company’s stock, valued at approximately $2,424,221.59. The trade was a 1.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Scotiabank began coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Ocular Therapeutix presently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Ocular Therapeutix Stock Performance

OCUL opened at $7.70 on Monday. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -5.83 and a beta of 1.23. The company’s fifty day moving average price is $8.68 and its two-hundred day moving average price is $9.02. Ocular Therapeutix, Inc. has a 1-year low of $4.06 and a 1-year high of $11.77. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.